[Laboratory and clinical studies on SM-4300 in the pediatric field].
The authors have carried out the laboratory and clinical studies of SM-4300 and obtained the following results. Serum level of IgG before and after administration of SM-4300 was observed in a case with agammaglobulinemia. The serum level reached the peak at 30 minutes after administration of SM-4300 and the half-life was about 25 days. SM-4300 enhanced the opsonic activity of human neutrophils to Pseudomonas aeruginosa in vitro. In substitution therapy against agammaglobulinemia, the clinical effect of SM-4300 was observed. Four patients with severe infections were treated with SM-4300 and antibiotics and evaluated. Clinical effects of SM-4300 in combination therapy with antibiotics were excellent in 2 cases, good in 1 case and poor in 1 case. The subjective and objective clinical side effects and abnormal laboratory findings were not noted.
D000361:Agammaglobulinemia / Q000276:immunology* / Q000628:therapy; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage / Q000378:metabolism; D007223:Infant; D007700:Kinetics; D008297:Male; D010587:Phagocytosis; D011550:Pseudomonas aeruginosa / Q000276:immunology; D011702:Pyelitis / Q000628:therapy; D012141:Respiratory Tract Infections / Q000628:therapy; D013210:Staphylococcus / Q000276:immunology
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300